Evidence map›Paper›PMID 30267257›Full record

Trial reportClinical drug investigation2018

Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.

Sara Nazha, Simon Tanguay, Anil Kapoor, Michael Jewett, Christian Kollmannsberger, Lori Wood, G A Georg Bjarnason, Daniel Heng, Denis Soulières, Martin Neil Reaume and 3 more

Abstract readComparative StudyPragmatic Clinical Trial
PubMed Publisher
In one paragraph

Trial report in Clinical drug investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal.Health technology assessment (Winchester, England) · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sara NazhaMcGill University Health Center, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-8135-0197
Simon TanguayMcGill University Health Center, Montreal, QC, Canada.
Anil KapoorMcMaster University, Hamilton, ON, Canada.
Michael JewettPrincess Margaret Cancer Center, Toronto, ON, Canada.
Christian KollmannsbergerUniversity of British Columbia, Vancouver, BC, Canada.
Lori WoodDalhousie University and Queen Elizabeth II Health Sciences Center, Halifax, NS, Canada.
G A Georg BjarnasonSunnybrooke Hospital, University of Toronto, Toronto, ON, Canada.
Daniel HengTom Baker Cancer Center, University of Calgary, Calgary, AB, Canada.
Denis SoulièresCentre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC, Canada.
Martin Neil ReaumeUniversity of Ottawa, Ottawa, ON, Canada.
Naveen BasappaCross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Eric LévesqueCentre Hospitalier Universitaire de Québec, Université de Laval, Quebec, QC, Canada.
Alice DragomirHealth Economics and Outcomes Research, Research Institute of the McGill University Health Center, Surgery/Urology, McGill University, 5252 Maisonneuve West, Montreal, QC, H4A 3S5, Canada. alice.dragomir@mcgill.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveThe development of new targeted therapies in kidney cancer has shaped disease management in the metastatic phase. Our study aims to conduct a cost-utility analysis of sunitinib versus pazopanib in first-line setting in Canada for metastatic renal cell carcinoma (mRCC) patients using real-world data.

methodsA Markov model with Monte-Carlo microsimulations was developed to estimate the clinical and economic outcomes of patients treated in first-line with sunitinib versus pazopanib. Transition probabilities were estimated using observational data from a Canadian database where real-life clinical practice was captured. The costs of therapies, disease progression, and management of adverse events were included in the model in Canadian dollars ($Can). Utility and disutility values were included for each health state. Incremental cost-utility ratio (ICUR) and incremental cost-effectiveness ratios (ICER) were calculated for a time horizon of 5 years, from the Canadian Healthcare System perspective.

resultsThe cost difference was $36,303 and the difference in quality-adjusted life year (QALY) was 0.54 in favour of sunitinib with an ICUR of $67,227/QALY for sunitinib versus pazopanib. The major cost component (56%) is related to best supportive care (BSC) where patients tend to stay for a longer period of time compared to other states. The difference in life years gained (LYG) between sunitinib and pazopanib was 1.21 LYG (33.51 vs 19.03 months) and the ICER was $30,002/LYG. Sensitivity analysis demonstrated the robustness of the model with a high probability of sunitinib being a cost-effective option when compared to pazopanib.

conclusionWhen using real-world evidence, sunitinib is found to be a cost-effective treatment compared to pazopanib in mRCC patients in Canada.

Indexed as

Cost-Benefit AnalysisAngiogenesis InhibitorsAntineoplastic AgentsCanadaCarcinoma, Renal CellFemaleHealth Care CostsHumansIndazolesKidney NeoplasmsMaleMarkov ChainsMiddle AgedPyrimidinesQuality-Adjusted Life YearsSulfonamidesAngiogenesis InhibitorsAntineoplastic AgentsIndazolespazopanibPyrimidinesSulfonamidesSunitinib

Identifiers

PMID30267257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.